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AbstrACt
Introduction Anxiety, mood and trauma-related 
disorders are common, affecting up to 20% of adults. 
Many of these individuals will experience symptoms 
of more than one disorder as diagnostically deined. 
However, most psychological treatments focus on 
individual disorders and are less effective for those 
who experience comorbid disorders. The Healthy 
and Resilient Mind Programme: Building Blocks for 
Mental Wellbeing (HARMONIC) trial introduces a novel 
transdiagnostic intervention (Shaping Healthy Minds 
(SHM)), which synthesises several evidence-based 
treatment techniques to address the gap in effective 
interventions for people with complex and comorbid 
dificulties. This early phase trial aims to estimate the 
eficacy and feasibility of the transdiagnostic intervention 
in preparation for a later-phase randomised controlled 
trial, and to explore mechanisms of change.
Methods/analysis We outline a patient-level two-arm 
randomised controlled trial (HARMONIC) that compares 
SHM to treatment-as-usual for individuals aged >18 
years (n=50) with comorbid mood, anxiety, obsessive-
compulsive or trauma/stressor disorders diagnoses, 
recruited from outpatient psychological services within 
the UK National Health Service (NHS). The co-primary 
outcomes will be 3-month follow-up scores on self-report 
measures of depressive symptoms, anxiety symptoms, and 
disability and functional impairment. Secondary outcomes 
include changes in symptoms linked to individual 
disorders. We will assess the feasibility and acceptability of 
SHM, the utility of proposed outcome measures, and reine 
the treatment manuals in preparation for a later-phase 
trial.
Ethics and dissemination This trial protocol has been 
approved by the Health Research Authority of the NHS 
of the UK (East of England, Reference: 16/EE/0095). We 
anticipate that trial indings will inform future revisions 
of clinical guidelines for numerous forms of mood, 
anxiety and stressor-related disorders. Findings will be 
disseminated broadly via peer-reviewed empirical journal 
articles, conference presentations, clinical workshops and 
a trial website.
trial registration NCT03143634; Pre-results.
Mood, stressor-related, obsessive-compulsive 
and anxiety disorders—the so-called common 
mental health problems (CMHP; National 
Institute for Health and Care Excellence 
(NICE), 2011)—are one of the largest causes 
of disability in the world, with 16%–20% of 
adults affected at any given time.1 2 Maxi-
mising our ability to treat CMHP in cost-effec-
tive, efficient and effective ways that can be 
widely disseminated is a priority.2 At present, 
there is a range of complex psychological 
treatments with demonstrated efficacy in 
the treatment of CMHP, and in preventing 
strengths and limitations of this study
 Ź The irst study to investigate the feasibility and pro-
cedural uncertainties of a lexibly delivered modu-
lar transdiagnostic treatment protocol—Shaping 
Healthy Minds (SHM)—in adults with unipolar mood, 
anxiety and stressor-related disorders.
 Ź This trial will provide a point estimate of eficacy 
of the SHM protocol, relative to treatment-as-usu-
al  (TAU), in preparation for a later-stage trial, and 
explore putative mediators and moderators of treat-
ment outcome.
 Ź Comparison of SHM against TAU currently provided 
by the National Health Service will provide a rigorous 
evaluation of treatment potential.
 Ź Administering self-report questionnaires that are 
speciic to each service  user’s secondary diag-
noses may limit the ability to draw group-based 
conclusions.
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recurrence. Consequently, NICE recommends psycho-
logical treatment at various points in the care pathway 
to all those suffering from such problems, although 
there are not specific recommendations for individuals 
experiencing more than one problem.3 Between 40% 
and 80% of patients experiencing a CMHP also expe-
rience an additional comorbid CMHP.4 5 Even our best 
available psychological treatments only achieve clinical 
recovery for 40%–70% of patients, depending on their 
primary CMHP, with people suffering complex comorbid 
conditions faring significantly worse.6 For the majority of 
patients who receive treatment, there remains a signifi-
cant risk of future relapse.7 8 A key challenge therefore 
is how we can build on and extend beyond the current 
psychological treatments for CMHP to increase effi-
cacy, and sustained recovery, particularly for those with 
comorbid, recurrent and complex presentations.9
Over the past decade, there has been a major shift in the 
conceptualisation of CMHP, away from a single-diagnosis 
approach in favour of a transdiagnostic model.10 11 There 
is strong empirical and theoretical support for develop-
ment of transdiagnostic treatment approaches, as many 
of the cognitive, emotional, behavioural and interper-
sonal factors which drive symptomatology are consistent 
across disorders.12 13 A transdiagnostic approach thereby 
has the potential to improve the efficacy and efficiency of 
treatment for people with anxiety, stress and depression.
There are potential limitations to the commonly used 
single-disorder-focused treatment approach. First, with 
the exception of a few existing programmes,14 15 most 
evidence-based treatment protocols are single-disor-
der-focused programmes (eg, depression,16 generalised 
anxiety,17 18 social anxiety19 and post-traumatic stress 
disorder20). Comorbid conditions and disorders are 
either ignored, or minimally treated within these treat-
ment packages. This leaves a mismatch between the 
available evidence base and the clinical reality which 
clinicians face: the majority of people with any given 
CMHP have at least one or more comorbid disorders to 
their primary diagnosis.4 Second, in the attempt to manu-
alise treatments, most packages are inflexible ‘one-size-
fits-all’ approaches, leaving patients with a wide range 
of problems and presentations receiving the same treat-
ment package, regardless of their symptoms, goals and 
concerns.14 Third, in practice, many clinicians already 
deliver evidence-based psychological treatments in a 
flexible manner in order to address individual concerns 
and goals. Manualised treatments need to better reflect 
the realities of service user experiences and treatment 
delivery. This approach merits improvement so that deliv-
ered treatments are more efficient, effective and person-
alised to individuals’ concerns.
Existing psychological treatments for CMHP share 
more similarities than differences.21 Despite differ-
ences in the theoretical foundation underlying avail-
able psychological treatments, and the terms used to 
describe maintaining factors and treatment targets, 
there are many common elements. For instance, 
psychoeducation, graded exposure, mindfulness tech-
niques and behavioural activation form a key component 
of a variety of effective treatments such as trauma-focused 
cognitive behavioural therapy (CBT), CBT, acceptance 
and commitment therapy (ACT), dialectical behaviour 
therapy (DBT), exposure therapy and mindfulness-based 
cognitive therapy (MBCT). The widespread availability 
of so many treatment options has the potential to elicit 
considerable decision-making difficulties for the treating 
clinician. In both formulation and treatment planning, 
challenging decisions occur when selecting the order in 
which to treat multiple difficulties, in evaluating the most 
appropriate treatment approach, and working out which 
treatment option will be acceptable and effective for the 
client.
A recent equivalence randomised controlled trial (RCT) 
demonstrated that a transdiagnostic protocol (The Unified 
Protocol for Transdiagnostic Treatment of Emotional Disorders)22 
and single-disorder protocols produced statistically equiv-
alent reduction in severity of principal anxiety disorder 
diagnosis, but that there was less attrition in the transdi-
agnostic group.23 Promising results have also been found 
for other transdiagnostic treatment protocols, including 
Norton’s Transdiagnostic Group Cognitive Behavioural 
Therapy for anxiety,15 Gros’s Transdiagnostic Behaviour 
Therapy for affective disorders24 and Schmidt’s False 
Safety Behaviour Elimination Therapy for anxiety disor-
ders.25 In addition, our systematic review and meta-analysis 
supported the overall efficacy of transdiagnostic treat-
ments.10 The review called for more high-quality studies 
to resolve uncertainties surrounding the heterogeneity 
of treatment effects and to determine the best treatment 
approaches and designs. We aim to address these issues 
through evaluating a novel intervention which combines 
a number of evidence-based treatment strategies. In using 
a modular approach, this trial will contribute to identi-
fication and evaluation of effective treatment compo-
nents and delivery method. The modular approach to 
treatment design incorporates self-contained functional 
units (therapy modules) that can operate independently 
and be delivered flexibly, and refer to other modules if 
needed.22 A complex, modular, tailored transdiagnostic 
intervention that targets common underlying processes 
maximises goodness of fit and has a direct focus on 
process rather than symptoms. The approach is thereby 
suitable for complexity and comorbidity as well as subsyn-
dromal and prodromal symptoms.
The transdiagnostic intervention we have developed—
Shaping Healthy Minds (SHM)—targets the processes 
and symptoms that are common to CMHPs and offers 
a number of advances in transdiagnostic treatment 
by incorporating the best available techniques from 
existing manual-based treatments into the one treatment 
package. A key aim of the programme is to encompass 
the treatment techniques that skilled psychologists and 
mental health clinicians already implement in standard 
practice for depressed, stressed and anxious patients with 
complex presentations.26 The intervention also builds 
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on the Unified Protocol for Transdiagnostic Treatment 
for Emotional Disorders described by Barlow et al,14 by 
working towards a prescriptive approach for the delivery 
of treatment modules based on the formulation of the 
client’s presenting difficulties.9 Specifically, the treat-
ment expands beyond interventions grounded in a sole 
treatment paradigm (eg, CBT) towards a theory-driven 
approach that uses efficacious techniques translated from 
basic science alongside components drawn from a wide 
range of evidence-based psychological treatments (eg, 
mindfulness-based interventions, ACT, behavioural acti-
vation and DBT).
The treatment protocol for SHM also changes the way 
that standardised manual-based treatments are deliv-
ered. Rather than using integral interventions (where 
all patients receive the same relatively fixed, complete 
protocol), the transdiagnostic intervention is a modular 
intervention, whereby the assessment of core problem-
atic areas of emotional, cognitive, interpersonal and 
behavioural processes informs the selection and sequence 
of treatment modules targeted at specific problem areas 
for patients.22 This modular approach allows for stan-
dardised, yet flexible treatment that is personalised 
to the individual concerns, problems and goals for the 
patient. Finally, it expands beyond interventions that 
typically focus on alleviating negative symptomatology 
(eg, negative thoughts, excessive negative emotions) and 
incorporates interventions designed to increase positive 
emotions, capture strengths and enhance resilience for 
sustained recovery.
We aim to examine the feasibility of SHM in 
reducing symptoms of depression, anxiety, distress, 
disability and functional impairment through an 
early stage RCT, in line with recommendations for the 
development of complex interventions.27 In partic-
ular, we will gather data on the extent to which SHM 
performs comparably to treatment-as-usual (TAU) for 
a given service user's primary diagnosed problem10 28 
as well as for other significant additional, secondary 
and/or comorbid difficulties. In addition, this trial 
will provide a preliminary evaluation of whether a 
modular transdiagnostic treatment approach may 
be effective at reducing the distress and impairment 
associated with CMHP.10 The trial will also provide 
an indication of the feasibility and acceptability of 
the transdiagnostic intervention to service users 
and clinicians by recruiting through postprimary 
care UK National Health Service (NHS) psychology 
services where complex comorbidity represents the 
modal clinical presentation. In addition, the trial will 
provide initial estimates of cost-effectiveness in terms 
of service use and potential quality-adjusted life years 
(QALYs) added. We therefore present the protocol 
for a feasibility trial with co-primary outcomes, exam-
ining the effect of SHM on primary and comorbid 
diagnoses. The feasibility trial will provide a plau-
sible range of point estimates of the efficacy of SHM 
on standardised continuous symptom measures for 
primary and secondary diagnoses to inform this key 
question, refine the treatment manual and contribute 
to the design of future scaled-up trials.27
MEthods And AnAlysIs
This trial protocol is written in compliance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials guidelines.
study design
The design is a parallel-arm RCT comparing SHM to TAU. 
Participants will be assessed three times—at baseline, at 
post-treatment and at 3 months follow-up. These three 
time points involve face-to-face assessments including 
the full battery of primary and additional outcomes and 
process measures, described below.
Participants and recruitment
The proposed feasibility study will seek to recruit 50 
people aged 18 years and above with a primary diagnosis 
of a unipolar mood, anxiety, obsessive-compulsive, or 
trauma-related and stressor-related disorder (CMHPs) 
with at least one additional comorbid diagnosis according 
to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5).29 Participants will be 
randomly allocated to one of two groups: (1) SHM or (2) 
TAU. Diagnosis of CMHPs will be determined by trained 
research staff using the Structured Clinical Interview for 
DSM-5 (SCID-5).30 To be eligible, participants will also 
need to score >10 on either the Patient Health Question-
naire (PHQ-9) or the Generalised Anxiety Disorder Ques-
tionnaire (GAD-7; see study measures below). Exclusion 
criteria are current/past psychosis or bipolar disorder, 
current diagnosis of alcohol or substance use disorder 
(all assessed via SCID-530), organic brain damage, 
complex trauma history or recurrent self-injury requiring 
specialist services, or current suicidality that warrants 
immediate clinical attention and constitutes a current 
risk of harm to the individual (all assessed via participant 
report and the clinical care team). Participants may be 
engaged with the multidisciplinary clinical care team, 
but those randomised to SHM will not be receiving other 
psychological services while participating in the trial. All 
other services (eg, medication review with psychiatrist or 
general practitioner, occupational therapy, social support 
services) may be continued, and there are no medication 
exclusions.
Participants will be recruited through local NHS clin-
ical psychology services, including the high-intensity 
team of the Cambridge Psychological Wellbeing Service, 
and secondary care services with expertise in treatment 
of more complex and comorbid affective disorders. The 
recruitment pathways will involve suitable service users 
on a waitlist to receive treatment being identified by a 
member of the clinical service (including an assistant 
psychologist focusing primarily on recruitment into clin-
ical research studies) who will provide them with a letter 
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outlining the study. Service users will then be able to 
contact the research team to opt into the study. Initial 
eligibility will be screened over the telephone, and suit-
able participants will be invited to complete the SCID, 
either at the clinical service or the research unit. At the 
beginning of this session, all participants will provide 
written informed consent (see supplementary materials 
for a sample Participant Information Sheet and Consent 
Form, online supplementary file 1). No potential partic-
ipants will be contacted by a member of the research 
team until they have given consent for such contact to a 
member of the clinical care team.
Participant allocation
Following both baseline assessment sessions, eligible 
participants will be stratified according to depres-
sion (PHQ-9) and anxiety (GAD-7) severity scores and 
randomised to either SHM (n=25) or TAU (n=25). This 
will be achieved using computer-generated, quasi-random 
numbers and will be conducted by the trial statistician 
(PW), blind to study objectives. Once generated, this 
information is passed to the project coordinator respon-
sible for delivering the intervention. Once a participant 
begins treatment, he or she is free to discontinue partici-
pation at any time, in which case she/he will be referred 
back to the appropriate NHS clinical care team. Figure 1 
summarises participant flow through the trial.
Interventions
SHM is a modular intervention, comprising 10 indepen-
dent modules that will last up to 20 sessions. The content 
of the modules is drawn from a number of evidence-based 
psychological therapies, including CBT,31 ACT,32 DBT,33 
MBCT34 and behavioural activation.35 36 The programme 
aims to bring together the core and unique therapeutic 
techniques from the best available disorder-focused treat-
ment packages into the one transdiagnostic treatment 
package (eg, behavioural experiments37 and graded expo-
sure38 from CBT, value exercises and mindfulness strate-
gies from ACT,39 activity scheduling from BA,35 emotion 
regulation strategies from DBT,33 and present moment 
awareness exercises from MBCT).40 The elements of SHM 
were drawn from recent meta-analyses supporting the 
effectiveness of these treatment strategies36 41–43, and the 
manuals were written and reviewed by experienced clin-
ical psychologists (TD, JMN, AB, CH and MB). In addi-
tion, experts in particular fields (eg, WK for mindfulness 
and case formulation) were consulted on the content of 
specific modules.
The modular approach is standardised, yet can be 
flexibly delivered according to an individual’s concerns, 
problems and goals.22 The treatment focuses both on alle-
viating negative symptoms and enhancing positive well-
being, by teaching skills and techniques and enhancing 
positive emotions, harness and build on strengths, and 
maximise resilience over the longer term. Choice, order 
and length of modules (ie, number of sessions over which 
they are completed) are tailored to the transdiagnostic 
difficulties of the individual using collaborative case 
formulation,44 although there are three core modules 
that everyone receives (outlined below). Treatment 
consists of weekly face-to-face 1 hour sessions with the trial 
therapists. Sessions will involve collaboratively setting an 
agenda for the session based on the participants’ ratings 
for their top three problems and top three strengths, the 
goals set for therapy, and the module in focus. Partici-
pants will complete homework exercises to consolidate 
and practice the skills learnt during the specific modules 
and will be strongly encouraged to continue this practice 
following the end of one module and move to the next.
The 10 SHM modules (core modules listed in bold) are: 
(1) Getting acquainted with SHM. (2) Understanding 
emotions. (3) Managing and tolerating emotions. (4) 
Behavioural activation. (5) Tackling avoidance. (6) Tack-
ling unhelpful thoughts. (7) Tackling unhelpful habits. 
(8) Overcoming repetitive thinking. (9) Managing upset-
ting memories and images. (10) Relapse prevention and 
future orientation. Additional information about the 
content of the modules can be found in the supplemen-
tary materials (online supplementary table 1).
treatment-as-usual
For TAU, clinical psychologists and high-intensity CBT 
therapists in teams specialising in CMHPs will be asked 
to provide the course of psychological therapy that 
they deem appropriate, in addition to referral to other 
health/social services and medication management. 
Psychological treatment in the specialist teams delivering 
TAU will standardly consist of disorder-focused CBT, Eye 
Movement Desensitisation Reprocessing or behavioural 
activation. The delivered treatment will be documented 
to ensure systematic understanding of the duration, 
frequency and type of treatment administered.
treatment integrity
Therapists with experience in treating adult CMHPs 
will deliver the transdiagnostic intervention. Treat-
ment fidelity and clinician adherence for the SHM 
group will be established using continued monitoring 
of completion of module components and through 
independent rating of specific treatment strategies 
by the supervising clinical psychologist. After every 
session, clinicians will complete a bespoke Treatment 
Fidelity Checklist which is a session-by-session self-re-
port measure of compliance with the SHM approach, 
and these will be evaluated during the weekly clin-
ical supervision with the trial clinical supervisor. In 
addition, a randomly selected 25% of the audio-taped 
treatment sessions will be rated for adherence to the 
manuals by an experienced clinician, independent of 
the trial. Homework completion will be monitored by 
trial therapists.
This bespoke measure will be supplemented with 
the Cognitive Therapy Scale-Revised (CTS-R)—a 
standardised measure of competence within cogni-
tive therapy, consisting of adherence to and skilful 
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application of cognitive therapy methods and the ther-
apeutic alliance.45 The CTS-R has 13 items that are 
completed by an independent rater, assessing agenda 
setting, feedback, collaboration, pacing and efficient 
use of time, interpersonal effectiveness, charisma/
flair, facilitation of emotional expression, guided 
discovery, conceptualisation, identifying key cogni-
tions, application of cognitive change methods, appli-
cation of behavioural techniques, use of homework.
MEAsurEs
Co-primary outcomes
The co-primary outcome measures are self-reported symp-
toms of depression and anxiety, indexed by PHQ-9,46 and 
GAD-7,47 as well as levels of disability and functional impair-
ment, indexed by the Work and Social Adjustment Scale.48
secondary outcomes
Given the transdiagnostic focus of the study, self-re-
ported symptoms on specific disorders that clients meet 
Figure 1 Participant low diagram for the HARMONIC trial with anticipated participant numbers at each stage. NHS, National 
Health Service.
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criteria for at trial baseline will be indexed by the IAPT 
Phobia Scales (social phobia, agoraphobia, specific 
phobia),49 the Social Phobia Inventory,50 the Penn State 
Worry Questionnaire (generalised anxiety),51 the Obses-
sive-Compulsive Inventory,52 the Revised Impact of Event 
Scale (post-traumatic stress),53 the Agoraphobia-Mobility 
Inventory,54 the Fear Questionnaire (specific phobias),55 
the Panic Disorder Severity Scale-self report version,56 
the Health Anxiety Inventory-short version57 and the 
Sheehan Disability Scale.58 Participants will only complete 
a selection of these measures depending on their 
concerns and associated diagnoses. In addition to these 
disorder-specific measures, the Inventory of Depression 
and Anxiety Symptoms will capture both disorder-spe-
cific and transdiagnostic symptom dimensionality within 
a single measure.59 Selection of these measures will be 
determined following completion of the structured clin-
ical interview at the beginning of assessment.
Process measures
We will also include a number of process-related 
measures which will be administered at baseline, postin-
tervention and at 3-month follow-up to begin to explore 
mechanisms of change and the feasibility of conducting 
embedded process outcome research within this type 
of trial (see table 1). To explore the value of the indi-
vidual modules administered within the transdiagnostic 
intervention, we will also administer module-relevant 
measures (eg, rumination, distress tolerance) before and 
after completion of the module. Finally, participants’ 
expectancy of treatment outcomes and measures of 
engagement and compliance will be administered prein-
tervention and postintervention to inform the further 
development of the protocol.
health economics measures
Data collection for the health economic evaluation will 
take a patient-level perspective,60 61 recording the cost 
per session of treatment and productivity losses resulting 
from time off work as a consequence of their mental 
health difficulties. Data will be collected using the Health-
lines Resource Use Questionnaire,60 61 which is a measure 
of the participants' use of healthcare services (including 
NHS, help at home), occupational productivity (ie, time 
off work) and cost of transdiagnostic treatment delivery 
(eg, direct and indirect time spent in service delivery). 
Table 1 Additional outcome and process measures to assess changes in potential mechanisms of psychological distress and 
in response to speciic transdiagnostic intervention modules
Measure Focus area
The Treatment Credibility/
Expectancy Questionnaire (CEQ)64
Expectancy about treatment outcome, as well as the credibility of the treatment
Cognitive Emotion Regulation 
Questionnaire (CERQ)65
Ability to contextualise negative events within a wider frame of reference
The Experiences Questionnaire (EQ)66 Ability to disengage from troublesome mental content and take a more accepting 
stance towards it, as well as the tendency to engage in rumination
Differential Emotions Scale (DES67) Intensity with which they experience different emotions on a typical day to obtain 
summary scores for positive emotions, negative emotions and denied emotions 
(the number of emotions not endorsed by the participant)
Levels of Personality Functioning Scale 
(LPFS)68
Personality functioning based on the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) alternative model of personality disorders. It has 
four subscales: identity, self-direction, empathy and intimacy
Ruminative Responses Scale of the 
Response Styles Questionnaire (RRS)69
Rumination (Module 7—Overcoming repetitive thinking)
Distress Tolerance Scale (DTS)70 Ability to tolerate distress (Module 3—Managing and tolerating emotions)
Dificulties with Emotion Regulation Scale 
(DERS)71
Ability to label, perceive and regulate emotions (Modules 2—Understanding 
emotions and 3—Managing and tolerating emotions)
Dysfunctional Attitudes Scale (DAS) short 
form (versions 1 and 2)72
Negative beliefs, thoughts and assumptions (Module 6—Tackling unhelpful 
thoughts)
Kentucky Inventory of Mindfulness Skills 
(KIMS)73
Mindful awareness (Module 2—Understanding emotions)
Anxiety Sensitivity Index (ASI)74 Fear of physical anxiety sensations (Module 3—Managing and tolerating emotions 
and Module 5—Tackling avoidance)
Post-traumatic Cognitions Inventory–short 
version (PTCI)75
Trauma-related beliefs and maladaptive appraisals of intrusive symptoms (Module 
9—Managing upsetting memories and images)
Skills of Cognitive Therapy76 Implementation of cognitive therapy skills (Module 6—Tackling unhelpful thoughts)
The Multidimensional Experiential 
Avoidance Questionnaire77
Avoidance of internal experiences including thoughts, feelings, physical sensations 
(Module 5—Tackling avoidance)
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The Medical Outcomes Study Questionnaire Short Form 
36 Health Survey (SF-36),62 a generic quality of life ques-
tionnaire, will measure overall health and well-being, daily 
functioning and general life satisfaction across multiple 
domains. These measures allow calculation of the addi-
tional number of quality of life years the treatment will 
yield. These data will allow preliminary estimates of the 
potential cost utility of the transdiagnostic intervention 
and also of the feasibility of acquiring these data within 
the trial protocol.
MEthodologICAl AsPECts
Power analysis and sample size
Although a standard power calculation based on detecting 
treatment effects is the conventional approach to deter-
mining sample sizes for trials, the main aim of the current 
trial is to elucidate feasibility for a larger later-stage eval-
uation. We therefore sought at this stage only to provide 
a point estimate of the effect of SHM to inform a power 
calculation for this putative fully powered later-phase eval-
uation. Our previous experience with such early phase 
trial platforms indicates that 50 patients will provide 
sufficient numbers and diagnostic diversity to evaluate 
feasibility, acceptability and procedural uncertainty for 
SHM and a plausible test of recruitment protocols. This 
will give 40 patients (20 per arm) at 3-month post-treat-
ment follow-up, assuming 20% attrition. This will provide 
a reasonable range of point estimates of effect on our set 
of candidate outcome measures sufficient to guide later 
phase trial work.
data collection and conidentiality
Outcome data for all participants who are randomised 
will be collected via face-to-face interviews and written 
questionnaires at baseline, post-treatment and 3-month 
follow-up. To maintain confidentiality, all participants 
will be given a trial number so that personally identifying 
information is not linked to assessment or trial informa-
tion. All data (including personally identifiable informa-
tion) will be stored on secure UK NHS databases, secure 
University of Cambridge servers and within locked filing 
cabinets under the management of the trial coordinator. 
Access will be limited to the immediate clinical research 
team.
blinding
Outcome assessments will be conducted by independent 
raters who have no therapeutic relationship with the 
patients and are blind to treatment condition. Double 
blinding of patients and therapists is not possible due to 
the nature of the trial (ie, a psychological intervention). 
Unblinding will not be necessary because participants 
and therapists are not blinded to intervention allocation.
statistical analysis plan
Initial analyses of the outcomes will be conducted by 
the trial statistician, blind to trial condition, following 
Consolidated Standards of Reporting Trials (CONSORT) 
standards (see online supplementary figure file 2). There 
are no planned interim analyses. Initial analyses will be 
conducted on an intention-to-treat basis, with subsequent 
analyses being per protocol. Mixed-model analyses of vari-
ance will be used to compare groups on outcomes at the 
three assessment points—baseline, postintervention and 
3-month follow-up. Baseline levels on relevant measures 
will be included as covariates, as appropriate. Both intent-
to-treat and per-protocol exploratory analyses will be 
conducted with our range of outcome measures following 
CONSORT standards. Multiple imputation will be used to 
account for missing data. Intent-to-treat analysis will also 
be used for those lost to attrition. Exploratory moderation 
and mediation analyses to examine process variables will 
be conducted using the MacArthur approach.63 For the 
health economic data, costs associated with service use 
will be calculated by attaching a unit cost to each instance 
of use, and data will be combined with QALYs62 derived 
from the SF-36 to arrive at a preliminary estimate of the 
cost utility of the transdiagnostic intervention.
Monitoring and data management
The trial will take place at NHS sites and a research 
unit in the East of England. A Trial Management Group 
(TMG), will meet one to two times a year to: manage the 
protocol; monitor recruitment in relation to targets; deal 
with any adverse events; and coordinate the different 
stages of the project. The TMG consists of research clin-
ical psychologists and assistant psychologists, a psychia-
trist, a health economist, clinical psychology researchers, 
the trial statistician, a nurse practitioner and a service 
user representative. Day-to-day project management will 
be the responsibility of a smaller trial team, meeting fort-
nightly to deal with administrative issues, troubleshooting 
and recruitment flow. Clinical supervision will take place 
fortnightly. As this is a phase I/II trial, a data manage-
ment committee was deemed unnecessary, and as such 
the trial team are responsible for monitoring and data 
management. Data will be monitored for completeness 
and consistency using spot checks and plausibility checks 
carried out by the trial statistician. The trial lead, trial 
coordinator and statistician will have full access to the 
final trial data set. The study data will be reported in line 
with the current CONSORT recommendations.
Patient and public involvement
Most broadly, the driving force behind the develop-
ment of SHM has been feedback from many hundreds 
of service users in clinical settings, specifically related to 
the suitability of treatments for complex and comorbid 
CMHPs. A Lived Experience Group comprising service 
users and carers hosted by the Cambridge Centre for 
Affective Disorders discussed the details of the current 
study at its meeting on 12 November 2013. This group 
provided useful feedback to the research team in terms 
of the materials for service users (eg, consent forms), the 
clinical setting for the intervention, and optimal forms of 
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Patient and Public Involvement (PPI) involvement (specif-
ically, the use of service user researchers to conduct qual-
itative interviews with service users). Further, we received 
service user input on the content of the draft treatment 
modules, and a part of this feasibility trial will be receiving 
feedback from participants on their experience of partic-
ipating in the trial and using the manuals. We will send 
all participants a report describing the findings and their 
implications. We will also make participants aware of the 
study website. There will be a number of roles following 
completion of recruitment including the refinement and 
revision of the treatment manual along with involvement 
in the academic output preparation.
EthICs And dIssEMInAtIon
Ethical approval and protocol amendments
 The study will be conducted within appropriate UK 
MRC, NHS and professional ethical guidelines, ensuring 
that Good Clinical Practice procedures are adhered to at 
all times. Protocol amendments will be circulated to the 
ethics committee, and trial team, and published in the 
online registration of the trial, and in the trial paper.
safety aspects
Adverse events are managed in line with UK Medical 
Research Council (MRC) protocols and, in the unlikely 
case of an adverse event, will be documented appropri-
ately. Precautions have been taken to reduce the likeli-
hood of adverse events occurring; for example, patients 
who are acutely suicidal or at high risk of harm do not 
meet study inclusion criteria. The interventions are deliv-
ered by therapists experienced in the management of risk 
and in the treatment of psychological disorders. In the 
case of any adverse events as a result of the intervention 
that would interfere with participation, participation in 
the trial will be discontinued. Regular team meetings will 
be conducted to monitor any difficulties patients may 
be having and ways of best dealing with these difficul-
ties. Serious adverse events will be reported to the ethics 
committee. The trial is underwritten by the University of 
Cambridge in the case that any individual suffers harm 
or requires post-trial care. Any adverse events will be 
reported in the trial paper.
dissemination policy
There are no publication restrictions and findings will be 
disseminated broadly to participants, healthcare profes-
sionals, the public and other relevant groups. Academic 
outputs will take the form of peer-reviewed empirical 
journal articles, commentary pieces and conference 
presentations. Clinical outputs will be prioritised by the 
research team in order to maximise the impact of the 
findings with practitioners and commissioners. Outputs 
will comprise clinical conferences, workshops, service 
user groups and a study website that will make the inter-
vention materials and related measures generally avail-
able. We will send all participants a report describing the 
findings and their implications. We will also make partic-
ipants aware of the study website. We anticipate that trial 
findings will inform future revisions of clinical guidelines 
for numerous forms of mood, anxiety and stress disor-
ders, and the development of guidelines for comorbid 
conditions. Anonymised data from the trial will be made 
publicly available on an open access database.
dIsCussIon
A significant proportion of the cost of CMHPs is gener-
ated by adults suffering from complex and comorbid 
depression, stress and anxiety, where treatment non-re-
sponse, cross-sector service use across health, social 
care and housing, and loss of productivity are greatest. 
Providing effective interventions for these mental health 
problems therefore has the potential to reduce both 
long-term treatment costs as well as prevent large produc-
tivity losses. At present, most psychological interventions 
focus on specific diagnoses and many treatment manuals 
take a ‘one-size-fits-all’ approach. Current evidence-
based interventions only achieve clinical recovery for 
40%–70% of patients, with people suffering complex 
comorbid conditions faring significantly worse. This 
randomised controlled feasibility trial aims to pave the 
way for a scaled-up efficacy trial of a new transdiagnostic 
modular treatment for all CMHPs—SHM—that enables 
the flexible delivery of evidence-based techniques. This 
treatment approach may improve the effectiveness and 
dissemination of evidence-based interventions for the 
many individuals for whom diagnosis-specific treatments 
leave significant difficulties unaddressed. The results from 
this trial will provide a range of estimates of effect sizes 
that can be used to power a later-stage trial of treatment 
efficacy, to refine the treatment protocol and to inform 
future evaluation of the mechanisms underlying any 
treatment effects. If effective, SHM has the potential to 
improve outcome for those with complex presentations, 
through offering a cost-effective treatment option to 
reduce chronic, transdiagnostic psychological difficulties.
trial status
This trial was registered at  clinicaltrials. gov on 4 May 2017 
(NCT03143634). This article was submitted on 31 May 
2018. To date, 15 participants have met eligibility criteria 
for the study and have been randomised to a condition. 
The trial opened on 31 July 2017, and data collection 
aims to be completed by September 2019.
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